An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation

Guo, Yusheng; Ren, Yanqiao; Dong, Xiangjun; Kan, Xuefeng; Zheng, Chuansheng

doi:10.2147/jhc.s358539

Cited by 12 publications

(14 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…showed that post-ablation STAT3 (signal transducer and activator of transcription 3) activation is linked to increased distant tumor stimulation in animal models ( 48 ). In addition, studies found factors such as epithelial-mesenchymal transitions (EMTs), increased number of cancer stem cells (CSCs), sustained local inflammation and hypoxic microenvironment, and heat shock response could explain rapid tumor progression after thermal ablation ( 49 ).…”

Section: Post-ablation Inflammation: a Double-edged Swordmentioning

confidence: 99%

In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy

et al. 2023

View full text Add to dashboard Cite

Percutaneous tumor ablation is now a widely accepted minimally invasive local treatment option offered by interventional radiology and applied to various organs and tumor histology types. It utilizes extreme temperatures to achieve irreversible cellular injury, where ablated tumor interacts with surrounding tissue and host via tissue remodeling and inflammation, clinically manifesting as post-ablation syndrome. During this process, in-situ tumor vaccination occurs, in which tumor neoantigens are released from ablated tissue and can prime one’s immune system which would favorably affect both local and remote site disease control. Although successful in priming the immune system, this rarely turns into clinical benefits for local and systemic tumor control due to intrinsic negative immune modulation of the tumor microenvironment. A combination of ablation and immunotherapy has been employed to overcome these and has shown promising preliminary results of synergistic effect without significantly increased risk profiles. The aim of this article is to review the evidence on post-ablation immune response and its synergy with systemic immunotherapies.

show abstract

Section: Post-ablation Inflammation: a Double-edged Swordmentioning

confidence: 99%

In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The mechanism of combination therapy inhibiting and killing HCC is unclear, which may be the research directions in the future. In addition, the malignant degree of residual tumors after local treatment will increase, regardless of TACE or RFA ( 97 , 98 ). Whether OVs have the same killing effect on residual tumors or not remains to be explored, which may be one of the hotspots in the future.…”

Section: Ovs-mediated Cancer Combined Therapymentioning

confidence: 99%

Recent advances in oncolytic virus therapy for hepatocellular carcinoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a highly refractory cancer and the fourth leading cause of cancer-related mortality worldwide. Despite the development of a detailed treatment strategy for HCC, the survival rate remains unsatisfactory. Oncolytic virus has been extensively researched as a new cancer therapeutic agent in the treatment of HCC. Researchers have designed a variety of recombinant viruses based on natural oncolytic diseases, which can increase the targeting of oncolytic viruses to HCC and their survival in tumors, as well as kill tumor cells and inhibit the growth of HCC through a variety of mechanisms. The overall efficacy of oncolytic virus therapy is known to be influenced by anti-tumor immunity, toxic killing effect and inhibition of tumor angiogenesis, etc. Therefore, a comprehensive review of the multiple oncolytic mechanisms of oncolytic viruses in HCC has been conducted. So far, a large number of relevant clinical trials are under way or have been completed, and some encouraging results have been obtained. Studies have shown that oncolytic virus combined with other HCC therapies may be a feasible method, including local therapy, chemotherapy, molecular targeted therapy and immunotherapy. In addition, different delivery routes for oncolytic viruses have been studied so far. These studies make oncolytic virus a new and attractive drug for the treatment of HCC.

show abstract

“…An increasing body of data suggests that EMT also participates in progression of HCC after RFA. Some studies have shown that P-ERK1/2 plays an important role in heatinduced EMT (34). Four studies (35)(36)(37)(38) performed heat treatment on MHCC97H, HepG2, HuH7, and HEP3B cell lines and found that ERK was significantly phosphorylated.…”

Section: Epithelial-mesenchymal Transitionmentioning

confidence: 99%

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research

Yao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains an important disease for health care systems in view of its high morbidity, mortality, and increasing incidence worldwide. Radiofrequency ablation (RFA) is preferred to surgery as a local treatment for HCC because it is safer, less traumatic, less painful, better tolerated, causes fewer adverse reactions, and allows more rapid postoperative recovery. The biggest shortcoming of RFA when used to treat HCC is the high incidence of residual tumor, which is often attributed to the vascular thermal deposition effect, the wide infiltration zone of peripheral venules, and the distance between satellite foci and the main focus of the cancer. Recurrence and progression of the residual tumor is the most important determinant of the prognosis. Therefore, it is important to be aware of the risk of recurrence and to improve the efficacy of RFA. This review summarizes the relevant literature and the possible mechanisms involved in progression of HCC after RFA. Current studies have demonstrated that multimodal treatments which RFA combined with other anti-cancer approaches can prevent progression of HCC after RFA.

show abstract

An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation

Cited by 12 publications

References 148 publications

In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy

In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy

Recent advances in oncolytic virus therapy for hepatocellular carcinoma

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research

Contact Info

Product

Resources

About